Lan Kluwe

Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2.

Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study.

Presymptomatic diagnosis for children of sporadic neurofibromatosis 2 patients: a method based on tumor analysis.

NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas.

Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy.

Treatment of ADHD in neurofibromatosis type 1.

Polyneuropathy in neurofibromatosis 2: clinical findings, molecular genetics and neuropathological alterations in sural nerve biopsy specimens.

Constitutional NF1 mutations in neurofibromatosis 1 patients with malignant peripheral nerve sheath tumors.

Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene.

Sulindac derivatives inhibit cell growth and induce apoptosis in primary cells from malignant peripheral nerve sheath tumors of NF1-patients.

Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients.

Somatic mitochondrial DNA mutations in neurofibromatosis type 1-associated tumors.

Screening for large mutations of the NF2 gene.

Prevalence of neurofibromatosis 1 in German children at elementary school enrollment.

Do hormonal contraceptives stimulate growth of neurofibromas? A survey on 59 NF1 patients.

Extensively high load of internal tumors determined by whole body MRI scanning in a patient with neurofibromatosis type 1 and a non-LCR-mediated 2-Mb deletion in 17q11.2.

Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene.

Unilateral vestibular schwannoma with other neurofibromatosis type 2-related tumors: clinical and molecular study of a unique phenotype.

Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues.

Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors.

Conservation of hotspots for recombination in low-copy repeats associated with the NF1 microdeletion.

Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs).

Type 2 NF1 deletions are highly unusual by virtue of the absence of nonallelic homologous recombination hotspots and an apparent preference for female mitotic recombination.

Telomerase activity is a biomarker for high grade malignant peripheral nerve sheath tumors in neurofibromatosis type 1 individuals.

Copy number variations in the NF1 gene region are infrequent and do not predispose to recurrent type-1 deletions.

Absence of cutaneous neurofibromas in an NF1 patient with an atypical deletion partially overlapping the common 1.4 Mb microdeleted region.

High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization.

Germline and somatic NF1 gene mutations in plexiform neurofibromas.

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromas.

Correlation of nonsense and frameshift mutations with severity of retinal abnormalities in neurofibromatosis 2.

The spectrum of somatic and germline NF1 mutations in NF1 patients with spinal neurofibromas.

Ral overactivation in malignant peripheral nerve sheath tumors.

Genome-wide high-resolution analysis of DNA copy number alterations in NF1-associated malignant peripheral nerve sheath tumors using 32K BAC array.

Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model.

Large intragenic deletions of the NF2 gene: breakpoints and associated phenotypes.

Extended runs of homozygosity at 17q11.2: an association with type-2 NF1 deletions?

Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden.

A novel third type of recurrent NF1 microdeletion mediated by nonallelic homologous recombination between LRRC37B-containing low-copy repeats in 17q11.2.

Intrachromosomal mitotic nonallelic homologous recombination is the major molecular mechanism underlying type-2 NF1 deletions.

Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.

Effects of splicing mutations on NF2-transcripts: transcript analysis and information theoretic predictions.

Monozygotic twins discordant for neurofibromatosis type 1 due to a postzygotic NF1 gene mutation.

Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits.

Cancer stem cell-like cells derived from malignant peripheral nerve sheath tumors.

MIA is a potential biomarker for tumour load in neurofibromatosis type 1.

Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.

Characterization of the nonallelic homologous recombination hotspot PRS3 associated with type-3 NF1 deletions.

Delineation of the clinical phenotype associated with non-mosaic type-2 NF1 deletions: two case reports.

Tissue-specific differences in the proportion of mosaic large NF1 deletions are suggestive of a selective growth advantage of hematopoietic del(+/-) stem cells.

Chinese herb mix Tiáo-Gēng-Tāng possesses antiaging and antioxidative effects and upregulates expression of estrogen receptors alpha and beta in ovariectomized rats.

Allelic drop-out, allele imbalance, or loss of heterozygosity?

Internal tumor burden in neurofibromatosis Type I patients with large NF1 deletions.

Ferritin light chain and squamous cell carcinoma antigen 1 are coreceptors for cellular attachment and entry of hepatitis B virus.

Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas.

Dissecting the clinical phenotype associated with mosaic type-2 NF1 microdeletions.

Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1.

Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions.

Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.

Efficacy and side effects of chinese herbal medicine for menopausal symptoms: a critical review.

P53 immunohistochemical expression does not correlate with clinical features in 207 carcinomas of the oral cavity and in the head and neck region.

Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.

Amplification of the PPFIA1 gene region on 11q13 in oral squamous cell carcinomas (OSCC).

Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors.

Immunohistochemical analysis of p16 expression, HPV infection and its prognostic utility in oral squamous cell carcinoma.

Immunohistochemical and FISH analysis of EGFR and its prognostic value in patients with oral squamous cell carcinoma.

Postoperative bleeding risk for cutaneous surgery in the head and neck region with continued phenprocoumon therapy.

Efficacy and selectivity of nilotinib on NF1-associated tumors in vitro.

Prognostic relevance of circulating tumor cells in blood and disseminated tumor cells in bone marrow of patients with squamous cell carcinoma of the oral cavity.

B-scan ultrasonographic monitoring of orthotopic xenografted plexiform neurofibroma in mice.

Lack of evidence for predictive and prognostic value of cyclin D1 gene polymorphism CCND1 G870A for oral squamous cell carcinoma.

Fractal dimension of time-resolved autofluorescence discriminates tumour from healthy tissues in the oral cavity.

Differences of 25-hydroxyvitamin D3 concentrations in children and adults with neurofibromatosis type 1.

Lack of evidence for increased risk of postoperative bleeding after cutaneous surgery in the head and neck in patients taking aspirin.

Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.

Lack of evidence for increased postoperative bleeding risk for dental osteotomy with continued aspirin therapy.

Efficacy and side-effects of a semi-individualized Chinese herb mixture "Tiáo Gēng Tāng" for menopausal syndrome in China.

Postoperative bleeding risk for oral surgery under continued clopidogrel antiplatelet therapy.

Is immediate bony microsurgical reconstruction after head and neck tumor ablation associated with a higher rate of local recurrence?

Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.

Quantitative associations of scalp and body subcutaneous neurofibromas with internal plexiform tumors in neurofibromatosis 1.

Optimized in vitro procedure for assessing the cytocompatibility of magnesium-based biomaterials.

Increased Postoperative Bleeding Risk among Patients with Local Flap Surgery under Continued Clopidogrel Therapy.

Postoperative bleeding risk for oral surgery under continued rivaroxaban anticoagulant therapy.

A novel genetic- and cell-based tool for assessing the efficacy and toxicity of anticancer drugs in vitro.